Remove tag mrna-vaccines
article thumbnail

Further insight into breakthroughs in mRNA drug discovery 

Drug Discovery World

DDW recently hosted Where are the breakthroughs in mRNA drug discovery and development? In this webinar, sponsored by Elegen, attendees learnt about the breakthroughs in mRNA drug discovery and development. We have shown that the excipient does not only work for our SNAP-tag lipid (SNaP) LNP, but also for the commercialised vaccines.

Drugs 52
article thumbnail

The Covid cash cow – a look at the Covid vaccine sales figures

pharmaphorum

The race to find and bring vaccines to market to fight Covid was impressive. It’s been almost a year since the first Covid vaccine was authorised for use. The mRNA jab, developed by Pfizer and BioNTech, launched to huge fanfare in December 2020 and promised the start of the end of the coronavirus pandemic.

Sales 137
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Next-generation immunotherapies The fourth track of PEGS Europe 2023 on the third day is ‘Next-generation immunotherapies’, which will feature a range of sessions made up of presentations, talks and posters which address cell-based immunotherapies, vaccines, and checkpoints and agonists.

Protein 59
article thumbnail

Pharma By The Numbers: A Retrospective Look at the Industry and 20 Years of Xtalks History

XTalks

Pfizer is also the co-developer of what is arguably the most successful COVID-19 vaccine rollout. Top-Selling Drugs by Year It’s no surprise that the best-selling drug of 2022 was Pfizer/BioNTech’s COVID-19 vaccine, Comirnaty (COVID-19 vaccine, mRNA). Just shy of 400 million doses have been administered in the US alone.

article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

to $3.65, Primarily Reflecting Updates to Anticipated Contributions from BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well as Other mRNA-Based Development Programs and COVID-19 Antivirals. Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 Adjusted Income (2).

article thumbnail

Merck KGaA raises full-year forecast; Perlmutter’s new gig tackles ‘undruggable targets’

The Pharma Data

. White House will make unordered vaccine supply available to other states ( WaPo ). White House set to send vaccines abroad ( Politico ). cases, vaccinations continue to drop as White House sets new inoculation goal ( CNBC ). inoculations ( CNBC ). CDC projects a surge in U.S. .